Financing

Proceeds from (Repayments of) Short-Term Debt

Merck & Co. Proceeds from (Repayments of) Short-Term Debt increased by 6973.3% to $1.06B in Q1 2026 compared to the prior quarter.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026May 4, 2026

How to read this metric

Frequent reliance on short-term debt may indicate working capital volatility, while consistent repayment suggests strong cash flow generation.

Detailed definition

The net cash flow resulting from the issuance and repayment of short-term debt, such as commercial paper or revolving cr...

Peer comparison

Standard metric for companies with seasonal or cyclical working capital requirements.

Metric ID: financing_proceeds_from_repayments_of_short_term_debt

Historical Data

12 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value-$4.77B$0.00-$3.00M$0.00$0.00$0.00$0.00$0.00$0.00$48.00M$15.00M$1.06B
QoQ Change+100.0%+100.0%-68.8%>999%
YoY Change+100.0%+100.0%
Range-$4.77B$1.06B
CAGR-42.1%
Avg YoY Growth+100.0%
Median YoY Growth+100.0%

Frequently Asked Questions

What is Merck & Co.'s proceeds from (repayments of) short-term debt?
Merck & Co. (MRK) reported proceeds from (repayments of) short-term debt of $1.06B in Q1 2026.
What does proceeds from (repayments of) short-term debt mean?
Net cash changes from short-term borrowing and repayment.